Table 1.

List of clinical targeted therapeutic agents inducing an adaptive response in cancer cells

Adaptive response	Drugs (generic name)	Trade name	Drug type	Target protein	Cancer	Reference
Autophagy	Afatinib	Gilotrif	Tyrosine kinase inhibitor	EGFR	NSCLC	204
	Bevacizumab	Avastin	Monoclonal antibody	VEGF-A	CRC	30
					GBM	205
	Bortezomib	Velcade	Proteasome inhibitor	26S proteasome	Breast cancer	97,206
	Cetuximab	Erbitux	Fv (variable, antigen-binding) regions of monoclonal antibody	EGFR	Lung cancer, CRC	59
	Dasatinib	Sprycel	Tyrosine kinase inhibitor	BCR/ABL, Src family	NSCLC	207
	Gefitinib	Iressa	Tyrosine kinase inhibitor	EGFR	Breast cancer	65
	Idelalisib	Zydelig	PI3K inhibitor	P110 delta	CML	98
	Lapatinib	Tykerb	Tyrosine kinase inhibitor	EGFR, HER2	Breast cancer	208
					HCC	209
	Osimertinib	Tagrisso	Tyrosine kinase inhibitor	EGFR	NSCLC	210
	Sorafenib	Nexavar	Tyrosine kinase inhibitor	Raf, PDGF, VEGFR2/3, Kit	RCC	211
	Sunitinib	Sutent	Tyrosine kinase inhibitor	PDGFR, VEGFR, KIT	HCC	212
					mRCC	213
					PanNET	214
	Trametinib	Mekinist	MEK kinase inhibitor	MEK1/2	Melanoma	215
					Leukemia	216
	Trastuzumab	Herceptin	Monoclonal antibody	HER2	Breast cancer	217–219
	Vemurafenib	Zelboraf	Competitive kinase inhibitor	BRAF (V600E)	Melanoma	220
	Vismodegib	Erivedge	Cyclopamine-competitive antagonist	SMO	CML	221
ER stress	Bortezomib	Velcade	Proteasome inhibitor	26S proteasome	Breast cancer	97
	Trastuzumab	Herceptin	Monoclonal antibody	HER2	Breast cancer	222
SASP	Sunitinib	Sutent	Tyrosine kinase inhibitor	PDGFR, VEGFR, KIT	Breast cancer	193

EGFR, epidermal growth factor receptor; VEGF-A, vascular endothelial growth actor A; HER2, human epidermal growth factor receptor 2; MEK1/2, mitogen-activated protein kinase kinase 1/2; VEGFR, vascular endothelial growth factor receptor; SMO, smoothened; NSCLC, non-small cell lung cancer; CRC, colorectal cancer; GBM, glioblastoma; CML, chronic myeloid leukemia; HCC, hepatocellular carcinoma; mRCC, metastatic renal cell carcinoma; PanNET, pancreatic neuroendocrine tumors.